TRANSCEND-T2D-1 detailed results are scheduled for the American Diabetes Association Scientific Sessions in June 2026
Until robust phase III clinical trial data becomes available comparing transdermal and injectable GLP-1 formulations directly, healthcare professionals must rely on established injectable therapies with proven efficacy and safety profiles for managing type 2 diabetes and obesity
They can advise on the legal and clinical risks, and may be able to signpost you towards legitimate clinical trial opportunities via the NIHR 'Be Part of Research' website or ClinicalTrials.gov
The starting price looks lower, but the total cost over a treatment course can exceed what you would pay with a flat-rate provider
These results suggest that the growth inhibitor of the delta cells exerts a sustained inhibitory effect on the secretion of insulin and glucagon, and that it may promote the responses of the islets to activation by cholinergic stimuli
A consultation is essential to assess needs accurately and design a phased treatment plan aligned with long-term goals
